Kudos’ Post

Popular drug that treats diabetes can reduce blood cancer risk Full Article Link >>> https://lnkd.in/g2rXJgff A new study has found the cancer preventive property of metformin, a common diabetes drug . The study by Danish researchers has found an association between metformin use and decreased risk of MPN or myeloproliferative neoplasm, a rare type of blood cancer . “Many other studies have investigated the association between metformin use and risk […] . . Latest IND . . . . #trendingnews #newstrending #trendingtopicnews #lifestyle #business #news #healthylifestyle #smallbusiness #supportsmallbusiness #lifestyleblogger #luxurylifestyle #businessowner #businesswoman #smallbusinessowner #businessnews

I haven't been able to access the full paper but had no idea about the extent of the 'survived cancer : chronic pain' story until we started to look at our MRX CBD trial to treat chemotherapy induced neuropathic pain. One of the markers we will measure in the placebo controlled, double blind crossover design is neuro-inflammation (using fMRI). It is going to be fascinating but more importantly an important step in helping patients deal with this incredibly debilatating condition. Our ambition is to make MRX1, our patent pending CBD medicine, available on the NHS. Our mantra is 'CBD based medicines for everyone who needs them, not only those who can afford them'. We simply must make CBD based medicines affordable and accessible. #chemotherapy #chemotherapyinducedpain #neuropathy #cbd

Could a common cholesterol-lowering drug hold the key to cancer prevention? Recent studies suggest that statins' anti-inflammatory properties might help prevent certain cancers. Explore the science behind this potential breakthrough in the Healthline article. Read more: https://lnkd.in/gTZ8qYjM Share your thoughts with us in the comments! #medicalresearch #clinicaltrials #medicalstudies #miamiclinicalresearch #statins #cholesterol #cancerprevention #cardiovascularhealth #hearthealth #healthresearch #cancertreatment #cancerresearch

March is World Myeloma Action Month. It is a chronic malignant disease of the blood system. Unlike many other types of cancer, it does not manifest itself as a single tumor, but as an accumulation of abnormal plasma cells in the bone marrow and the presence of abnormal protein in the blood. This is a fairly rare cancer, diagnosed most often in elderly people, and the main causes of its occurrence have not yet been identified. Provoking factors may include genetic predisposition, radiation, exposure to toxic chemicals and others. Throughout March, people with myeloma, as well as their families, friends and caregivers, are raising awareness of the disease and advocating for action initiatives. Myeloma disease is diagnosed and treated by a hematologic oncologist, a physician who specializes in malignant neoplasms of the blood. Laboratory and instrumental diagnostic methods, examination and interview of the patient are used to make a diagnosis. Approaches to the treatment of multiple myeloma differ depending on the patient's condition, stage of the disease, etc. Currently, multiple myeloma is completely incurable, but new drugs and modern innovative therapy allow patients to go into long-term remission - this is a huge scientific breakthrough. After basic therapy, periodic check-ups (every 3-6 months) and maintenance therapy are required. To find out more about GCT’s experience in Oncology Clinical Trials you can contact us at bd@gctrials.com. https://lnkd.in/dD4_Ebas   #GCT_awareness #MyelomaActionMonth #Myeloma #Cancer #GCT #GlobalClinicalTrials #CRO #clinicalresearch #drugdevelopment #medicine #pharma #clinicaltrials #clinicaltrial #gctrials #research 

Popular drug that treats diabetes can reduce blood cancer risk Full Article Link >>> https://lnkd.in/g6MRZcSQ A new study has found the cancer preventive property of metformin, a common diabetes drug . The study by Danish researchers has found an association between metformin use and decreased risk of MPN or myeloproliferative neoplasm, a rare type of blood cancer . “Many other studies have investigated the association between metformin use and risk […] . . Latest IND . . . . #trendingnews #newstrending #trendingtopicnews #lifestyle #business #news #healthylifestyle #smallbusiness #supportsmallbusiness #lifestyleblogger #luxurylifestyle #businessowner #businesswoman #smallbusinessowner #businessnews

Niktimvo (axatilimab) - Mechanism of Action On August 14, 2024, FDA approved Niktimvo (axatilimab-csfr) for the treatment of patients with chronic graft-vs-host disease (cGVHD) who have progressed on at least 2 prior lines of systemic therapy. https://lnkd.in/gWDavwdz Axatilimab is a monoclonal antibody that targets colony stimulating factor-1 receptor, or CSF-1R, a cell surface protein thought to control the survival and function of monocytes and macrophages. In pre-clinical models, inhibition of signaling through the CSF-1 receptor has been shown to reduce the number of disease-mediating macrophages along with their monocyte precursors, which has been shown to play a key role in the fibrotic disease process underlying diseases such as chronic graft-versus-host disease (GVHD) and idiopathic pulmonary fibrosis (IPF). The recommended dose of axatilimab dose in patients who weigh at least 40 kg is 0.3 mg/kg, up to a maximum dose of 35 mg, as an intravenous infusion administered over 30 minutes every 2 weeks until disease progression or unacceptable toxicity. #Cancer #Oncology #Niktimvo #axatilimab #BoneMarrowTransplant #HSCT #GVHD #cGVHD #Moffitt #MoffittCancerCenter Moffitt Cancer Center

🔬Johnson & Johnson's Rybrevant-Lazcluze as First-Line NSCLC Treatment (August 20, 2024) This is a brand-new update as of August 20th! Johnson & Johnson's combination of Rybrevant and Lazcluze has just received FDA approval as the first chemotherapy-free, first-line treatment for patients with non-small cell lung cancer (NSCLC). This innovative treatment targets patients with EGFR mutations and has demonstrated a 30% reduction in the risk of disease progression or death compared to Tagrisso (osimertinib), along with a nine-month longer duration of response. https://lnkd.in/gSRw5mXg 🔬Low-Carb, High-Fat Diet Combined with Tomivosertib (eFT508) Stop Tumor Growth?! (August 14, 2024) University of California, San Francisco researchers have discovered a new potential treatment for pancreatic cancer by combining a low-carb, high-fat diet (also known as a ketogenic diet) with the drug tomivosertib (eFT508). The diet forces tumors to rely solely on fat for energy, and the drug blocks this fat metabolism, stopping tumor growth in mice. This approach could lead to personalized cancer treatments by targeting cancer cells' metabolic vulnerabilities. This promising finding suggests that manipulating diet alongside targeted therapies might open new avenues in cancer treatment, particularly for challenging cases like pancreatic cancer. https://lnkd.in/gVV_Kx5P #Oncology #CancerTreatment #NSCLC #LungCancer #PancreaticCancer #RybrevantLazcluze #Tomivosertib #PrecisionMedicine #CancerResearch #TargetedTherapy #Genecast #ADPS #LiquidBiopsy #CancerDiagnosis #MolecularDiagnostics

On August 14, 2024, the FDA approved Niktimvo (axatilimab-csfr) for the treatment of patients with chronic graft-versus-host disease (cGVHD) who have progressed on at least 2 prior lines of systemic therapy. Axatilimab is a monoclonal antibody that targets colony stimulating factor-1 receptor, or CSF-1R, a cell surface protein thought to control the survival and function of monocytes and macrophages. In pre-clinical models, inhibition of signaling through the CSF-1 receptor has been shown to reduce the number of disease-mediating macrophages along with their monocyte precursors, which has been shown to play a key role in the fibrotic disease process underlying diseases such as chronic graft-versus-host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The recommended dose of axatilimab dose in patients who weigh at least 40 kg is 0.3 mg/kg, up to a maximum dose of 35 mg, as an intravenous infusion administered over 30 minutes every 2 weeks until disease progression or unacceptable toxicity. #Cancer #Oncology #Niktimvo #axatilimab #BoneMarrowTransplant #HSCT #GVHD #cGVHD #Moffitt #MoffittCancerCenter Moffitt Cancer Center

Find out the research article Title: Statin prevents cancer development in chronic inflammation by blocking interleukin 33 expression. DOI: https://lnkd.in/g47uuX9G Discover how common cholesterol-lowering drugs, known as statins, might hold the key to cancer prevention. Learn about groundbreaking research that links statins to reduced cancer risk through inflammation control. Don’t miss out on this potential game-changer in cancer prevention! #Statins #CancerPrevention #ChronicInflammation #HeartHealth #IL33 #Cholesterol #CholesterolLowering #CancerResearch #Inflammation #Pitavastatin #HealthBreakthrough #ImmuneSystem #CancerRisk #HealthTips #Prevention #HealthInnovation #TLR3 #TLR4 #TBK1 #IRF3 #PancreaticCancer #HarvardResearch #MedicalBreakthrough #CholesterolDrugs #MassGeneralHospital #Immunology #Medicine #HealthBenefits #Cytokines #StatinBenefits #CancerTreatment #Oncology #ChronicDisease #HealthyLiving #HealthAwareness #Wellness #Healthcare #StatinDrugs #CancerAwareness #ScienceNews #MedicalResearch #StudyResults #DrugDiscovery #HealthRevolution #ScientificStudy #LifeSavingDrugs #ResearchFindings #MedicalNews #CancerPreventionTips #Pharmaceuticals #HealthAdvice #PublicHealth #Cardiology #PreventCancer #Biology #HealthScience #InnovativeResearch #WellnessJourney #HealthcareInnovation #FutureOfMedicine #DiseasePrevention #MedicalAdvancements #StayHealthy #MedicalBreakthroughs #NewResearch #HealthyHabits #FightCancer #HealthDiscoveries #ResearchInnovation #CuttingEdgeMedicine #PreventativeHealth #HealthyChoices #ScienceBreakthroughs #StatinTherapy #PharmaNews #OncologyResearch #CholesterolManagement #HealthAndWellness #MedicalInnovation #HealthEducation #InflammationControl #ImmuneHealth #PreventDisease #ScienceFacts #HealthBreakthroughs #NewHealthFindings #MedicalScience #CancerFighting #HealthExplained #ResearchBreakthroughs #MedicalDiscoveries #HealthNews #BreakthroughScience

New study shows non-statin cholesterol drugs may lower liver cancer risk! An observational study published in Cancer (American Cancer Society Journals), has found that non-statin cholesterol-lowering medications such as ezetimibe (marketed as #Zetia and #Ezetrol), are associated with a 31% lower risk of developing liver cancer. In contrast, other medications tested—fibrates, niacin, and omega-3 fatty acids—did not impact liver cancer risk. The effect of bile acid sequestrants was less clear, with a slight 5.31% increase in risk noted, warranting further research. While statins remain the primary choice for managing cholesterol, this study highlights the potential of non-statin options, particularly for those who experience side effects from statins or have specific health conditions. Read more here: https://lnkd.in/g_f-EfYu And find the study here: https://lnkd.in/gyKdX3dJ #Cholesterol #LiverCancer #NonStatin #Statins